M1 receptor Inhibitors
2 drugsAbout M1 receptor
The M1 receptor, a subtype of muscarinic acetylcholine receptors, binds acetylcholine and mediates neuronal signaling in the brain and other tissues. It plays a crucial role in various physiological processes.
M1 receptors are therapeutic targets, evidenced by two FDA-approved drugs, despite the lack of direct genetic evidence linking receptor variations to specific diseases. Further research is needed to fully elucidate therapeutic potential beyond current indications.
Two small molecule drugs target M1: TIOTROPIUM BROMIDE (Lupin) and TONMYA (TONIX), approved for respiratory and other indications, respectively. Approvals span from 2023 to 2025.
Strategic Insights
ℹ️ How we calculate- White space opportunity in High Tone Pelvic Floor Dysfunction with only 1 trials.
Top M1 receptor Drugs
The competitive landscape includes Lupin and TONIX, each with an approved drug.
Low market concentration suggests opportunities for new entrants, but also highlights potential challenges in establishing market share.
M1 receptor Drug Modality Landscape
Modalities
Routes of Administration
M1 receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore opportunities for novel modalities like antibodies or biologics to differentiate from existing small molecule drugs.
M1 receptor Clinical Trials 132 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 13 | 0 | 2 | 100% |
| Phase 2 | 26 | 21 | 4 | 1 | 84% |
| Phase 3 | 49 | 43 | 6 | 0 | 88% |
| Phase 4 | 42 | 39 | 3 | 0 | 93% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M1 receptor Drug Approval Timeline (2012 - 2025)
The first drug targeting M1 was approved in 2023, with the most recent in 2025.
Recent approvals suggest renewed interest in the target, but further approvals are needed to confirm sustained opportunity.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 61 clinical trials targeting M1 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities